Linezolid Impurity-H | CAS : 1236077-61-4

Certainly! Here's the complete summary including the structural differences and its relevance in pharmaceuticals:

This impurity differs from Linezolid primarily at the 5-position of the oxazolidinone ring, where the original N-aryl acetamide side chain is replaced by a benzylaminomethyl group. While it retains the (S)-configuration and the 3-fluoro-4-morpholinophenyl substitution at the 3-position, the substitution of the acetamide with a benzylamine moiety introduces a significant change in polarity and steric profile, distinguishing it structurally and functionally from the parent API.

In pharmaceutical development, identifying and characterizing such impurities is essential for ensuring drug safety, efficacy, and regulatory compliance. Structural variants like this may arise during synthesis or degradation and must be monitored to maintain the purity profile of Linezolid formulations. Understanding their formation and impact helps guide process optimization and supports robust quality control.